---
title: "Hengrui Medicine hits record low on weak H1 earnings, down 2%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296723923.md"
description: "Hengrui Medicine (1276.HK) hit an all-time low, down 2% to HK$47.50 after weak H1 results and HSBC target cut."
datetime: "2026-08-24T01:54:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296723923.md)
  - [en](https://longbridge.com/en/news/296723923.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296723923.md)
generator: "portal-rs"
---

# Hengrui Medicine hits record low on weak H1 earnings, down 2%

Hengrui Medicine (1276.HK) fell 2% during regular trading to HK$**47.50**, after touching HK$**47.42** earlier — an all-time low since listing — with turnover around HK$**224 million**.

The slide follows disappointing first-half results: revenue slipped **1.9%** year-on-year to **15.46 billion yuan**, while adjusted net profit dropped **12.7%** to **3.73 billion yuan**, as generic drug sales contracted **27%** in the second quarter and R&D spending rose. HSBC cut its price target to **HK$73.70** from **HK$88.50**, and Nomura flagged weaker-than-expected sales and profit. The stock shed **10.2%** last week, underperforming the Hang Seng Index by more than **12 percentage points**, while the short-selling ratio climbed **1.49%**. A proposed **1 billion-2 billion yuan** A-share buyback for an employee stock plan failed to stem the decline.

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)

## Related News & Research

- [Top Economist Slams Trump’s Venezuela Oil Deal ‘Theft’ — ‘Toppled Their Leader’ and ‘Had Him Sign Over Billions’](https://longbridge.com/en/news/298310697.md)
- [Citi: New Biomarker Evidence for INSILICO 's Rentosertib Supports Potential Anti-aging Effects](https://longbridge.com/en/news/298417588.md)
- [Fosun Trims Indian Pharma Stake While Retaining Control](https://longbridge.com/en/news/298132819.md)
- [Livzon Pharma Calls EGM to Approve Cross-Border Special Interim Dividend](https://longbridge.com/en/news/298301071.md)
- [CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China](https://longbridge.com/en/news/298433525.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**